LearnPricingTestimonialsFeatures
Log inSign up
Company News

Resistant microbes are already spreading. Most labs can't see it yet.

By
Sam Sihvonen

For most people, antimicrobial resistance (AMR), where microbes evolve to survive the drugs meant to kill them, is a headline about the future. In reality, it's already linked to more than 4.7 million deaths a year. Without urgent action, it could cause up to 39 million deaths by 2050 and cost the global economy over US$3.4 trillion a year (WOAH).

Today marks the start of World AMR Awareness Week, held every year from 18 to 24 November and organized by WHO, FAO, UNEP and WOAH. It is a global campaign, which aims to improve awareness and understanding of AMR.

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. Resistance develops through antibiotic use, especially overuse and misuse. Resistant bacteria can spread between people, animals, food and the environment.

At Solu, we're proud to take part in World AMR Awareness Week. Our work puts us alongside the hospital and public health labs that fight resistance every day.

Containing AMR starts with seeing how it spreads

Resistance doesn't only emerge through antibiotic use. It also spreads from patient to patient, especially in hospitals. Stopping that spread is one of the most direct ways to contain AMR, and it starts with knowing when it's happening.

Routine culture and antimicrobial susceptibility testing identify the bacterial species and its resistance profile. However, they offer limited resolution for determining whether isolates from different patients are closely related, which is key to detecting transmission within a hospital.

Whole-genome sequencing (WGS) offers much higher resolution. By comparing the complete genomes of isolates, it shows how closely related they are and which resistance genes they carry. Combined with epidemiological data, such as when and where patients were treated, this gives infection prevention teams stronger evidence on whether cases are linked.

WGS has become more affordable and is increasingly used in hospital and public health surveillance. The hard part is what comes next. Running and maintaining bioinformatics pipelines, comparing genomes and interpreting the WGS results take time and specialist skills that most labs don't have.

"Running bioinformatics pipelines, comparing genomes and interpreting the WGS results take time and specialist skills that most labs don't have."
Sam Sihvonen
CEO & co-founder, Solu

Making microbial genomic analysis accessible to every lab

That's why we started Solu. We want to make microbial genomics fast and accessible for every lab, not just the few with a bioinformatician on staff. Labs upload their sequencing data and get analysis results in minutes, with no pipelines to build or maintain. They can see which resistance genes their isolates carry and how closely they are related.

Today, hospital and public health labs in more than 14 countries use Solu in their surveillance work, and their results are a big part of why we believe routine genomic surveillance is within every lab's reach.

For example, in New Zealand, Awanui Labs and ESR re-analysed data from two past outbreaks in newborn units, one of them caused by MRSA (methicillin-resistant Staphylococcus aureus), and had median analysis times of 13 and 20 minutes, compared with off-site analysis that could take weeks.

Faster insight gives infection prevention teams more time to act. When answers arrive in minutes instead of weeks, genomic data can guide decisions while the situation is still unfolding, not just explain it afterwards.

"We want to make microbial genomics fast and accessible for every lab."
Sam Sihvonen
CEO & co-founder, Solu

One Health, one action

This year's WAAW theme is "One Health, one action: Prevent AMR now". Resistance moves between people, animals, food and the environment, so no single sector can contain it alone.

In hospitals, the most useful action is often simply acting sooner. As sequencing spreads to more labs and analysis gets faster, infection prevention teams no longer have to wait weeks to understand what they're dealing with. They can see sooner whether cases are linked and choose the right response. That can mean taking targeted measures when they are needed and avoiding unnecessary disruption when they are not. Acting earlier, and on better information, can help contain the spread of AMR.

"Acting earlier, and on better information, can help contain the spread of AMR."
Sam Sihvonen
CEO & co-founder, Solu

To everyone working on AMR in labs, on wards and in public health, thank you for the work you do, this week and every week.

Get started today

Upload your own samples and see the results in minutes.

Start free trial

Related posts

All posts →
Company News
Karolinska University Hospital chooses Solu to scale WGS analysis and reporting
Company News
Hôpital de La Tour Partners with Solu to Enhance Genomic Surveillance in Switzerland
Company News
Upgraded candida.app empowers global surveillance of deadly fungus Candida auris
Features
Candida.app
Trust Center
Learn
Research
Contact us
LinkedIn
Privacy policy
Terms & Conditions
hello@solugenomics.com
+358 40 1205369
© 2026 Solu Healthcare, Inc.